TR200002896T2 - Kalsilitik Bileşimler - Google Patents

Kalsilitik Bileşimler

Info

Publication number
TR200002896T2
TR200002896T2 TR2000/02896T TR200002896T TR200002896T2 TR 200002896 T2 TR200002896 T2 TR 200002896T2 TR 2000/02896 T TR2000/02896 T TR 2000/02896T TR 200002896 T TR200002896 T TR 200002896T TR 200002896 T2 TR200002896 T2 TR 200002896T2
Authority
TR
Turkey
Prior art keywords
calcilitic
compositions
compounds
calcylitic
new
Prior art date
Application number
TR2000/02896T
Other languages
English (en)
Turkish (tr)
Inventor
Kumar Bhatnagar Pradip
Lorraine Burgess Joelle
Francis Callahan James
Rolando Calvo Raul
G. Del Mar Eric
Amparo Lago Maria
T. Nguyen Thomas
Original Assignee
Smithkline Beecham Corporation
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Nps Pharmaceuticals, Inc. filed Critical Smithkline Beecham Corporation
Publication of TR200002896T2 publication Critical patent/TR200002896T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2000/02896T 1998-04-08 1999-04-08 Kalsilitik Bileşimler TR200002896T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8109398P 1998-04-08 1998-04-08

Publications (1)

Publication Number Publication Date
TR200002896T2 true TR200002896T2 (tr) 2001-01-22

Family

ID=22162059

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02896T TR200002896T2 (tr) 1998-04-08 1999-04-08 Kalsilitik Bileşimler

Country Status (33)

Country Link
US (1) US6395919B1 (enExample)
EP (1) EP1070048B1 (enExample)
JP (1) JP2002510671A (enExample)
KR (1) KR20010042526A (enExample)
CN (1) CN1304401A (enExample)
AP (1) AP1271A (enExample)
AR (1) AR018177A1 (enExample)
AT (1) ATE303358T1 (enExample)
AU (1) AU752389B2 (enExample)
BG (1) BG104916A (enExample)
BR (1) BR9909486A (enExample)
CA (1) CA2327279A1 (enExample)
CO (1) CO5031246A1 (enExample)
DE (1) DE69927008T2 (enExample)
DZ (1) DZ2751A1 (enExample)
EA (1) EA200001039A1 (enExample)
EG (1) EG24178A (enExample)
ES (1) ES2247795T3 (enExample)
HU (1) HUP0101346A3 (enExample)
ID (1) ID27004A (enExample)
IL (1) IL138918A0 (enExample)
MX (1) MXPA00009844A (enExample)
MY (1) MY121054A (enExample)
NO (1) NO20005006L (enExample)
NZ (1) NZ507288A (enExample)
OA (1) OA11499A (enExample)
PE (1) PE20000415A1 (enExample)
PL (1) PL343357A1 (enExample)
SK (1) SK14852000A3 (enExample)
TR (1) TR200002896T2 (enExample)
UA (1) UA58586C2 (enExample)
WO (1) WO1999051569A1 (enExample)
ZA (1) ZA200005369B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180628A1 (es) * 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
AU2001277752A1 (en) 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
ATE343390T1 (de) * 2000-10-25 2006-11-15 Smithkline Beecham Corp Kalzilytische verbindungen
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
ZA200505587B (en) 2003-04-23 2006-09-27 Japan Tobacco Inc Casr antagonist
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JP2007522148A (ja) * 2004-02-06 2007-08-09 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
ES2400693T3 (es) * 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
JP5628687B2 (ja) * 2008-12-24 2014-11-19 第一三共株式会社 インダニル化合物
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
DE3301198A1 (de) 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ES2158996T3 (es) * 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds

Also Published As

Publication number Publication date
CO5031246A1 (es) 2001-04-27
NZ507288A (en) 2003-05-30
ES2247795T3 (es) 2006-03-01
PL343357A1 (en) 2001-08-13
ZA200005369B (en) 2001-12-18
BR9909486A (pt) 2001-11-06
JP2002510671A (ja) 2002-04-09
AU3481999A (en) 1999-10-25
AU752389B2 (en) 2002-09-19
EP1070048B1 (en) 2005-08-31
IL138918A0 (en) 2001-11-25
AP1271A (en) 2004-04-21
NO20005006D0 (no) 2000-10-04
SK14852000A3 (sk) 2001-05-10
NO20005006L (no) 2000-10-04
DE69927008D1 (de) 2005-10-06
DZ2751A1 (fr) 2003-09-15
WO1999051569A1 (en) 1999-10-14
AR018177A1 (es) 2001-10-31
CN1304401A (zh) 2001-07-18
MXPA00009844A (es) 2003-07-14
PE20000415A1 (es) 2000-05-21
EG24178A (en) 2008-09-28
ATE303358T1 (de) 2005-09-15
OA11499A (en) 2004-05-05
HK1034243A1 (en) 2001-10-19
HUP0101346A3 (en) 2003-03-28
DE69927008T2 (de) 2006-03-16
ID27004A (id) 2001-02-22
EP1070048A1 (en) 2001-01-24
KR20010042526A (ko) 2001-05-25
CA2327279A1 (en) 1999-10-14
AP2000001931A0 (en) 2000-09-30
EA200001039A1 (ru) 2001-04-23
BG104916A (en) 2001-06-29
MY121054A (en) 2005-12-30
US6395919B1 (en) 2002-05-28
EP1070048A4 (en) 2001-11-07
HUP0101346A2 (hu) 2001-08-28
UA58586C2 (uk) 2003-08-15

Similar Documents

Publication Publication Date Title
TR200002896T2 (tr) Kalsilitik Bileşimler
TR200003244T2 (tr) Yeni kullanım
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
TR199900639T2 (xx) Olanzapin dihidrat D.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
SE9702773D0 (sv) Novel compounds
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
TR200001544T2 (tr) Yeni bileşikler.
SE9802729D0 (sv) Novel Compounds
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
EA199900373A2 (ru) Фармацевтические композиции
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
NO993350L (no) Vitronectin-reseptor-antagonister
TR199802284T2 (xx) Dopamin D3 resept�rlerinin mod�lat�rleri olarak tetrahidroizokuinolin t�revleri.
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
TR200000152T2 (tr) Yeni bileşikler.
AR016981A2 (es) Polipeptidos sinteticos
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
TR200103396T2 (tr) Anti-fas antikoru içeren farmasötik terkipler.
SE9802937D0 (sv) Novel compounds